[1]刘建伟,李聪伶,于海群.雷珠单抗玻璃体内注射对增生型糖尿病视网膜病变玻璃体切割术效果的影响[J].眼科新进展,2016,36(3):265-267.[doi:10.13389/j.cnki.rao.2016.0071]
　LIU Jian-Wei,LI Cong-Ling,YU Hai-Qun.Effects of intravitreal injection of ranibizumab on vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2016,36(3):265-267.[doi:10.13389/j.cnki.rao.2016.0071]
点击复制

雷珠单抗玻璃体内注射对增生型糖尿病视网膜病变玻璃体切割术效果的影响
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年3期
页码:
265-267
栏目:
应用研究
出版日期:
2016-03-05

文章信息/Info

Title:
Effects of intravitreal injection of ranibizumab on vitrectomy for proliferative diabetic retinopathy
作者:
刘建伟; 李聪伶; 于海群
261031　山东省潍坊市，潍坊医学院附属医院眼科
Author(s):
LIU Jian-Wei ;  LI Cong-Ling ; YU Hai-Qun
Department of Ophthalmology,the Affiliated Hospital of Weifang Medical University,Weifang 261031, Shandong Province,China
关键词:
增生型糖尿病视网膜病变; 雷珠单抗; 玻璃体切割术
Keywords:
proliferative diabetic retinopathy ; ranibizumab ;  vitrectomy
DOI:
10.13389/j.cnki.rao.2016.0071
文献标志码:
A
摘要:
目的　探讨术前玻璃体内注射雷珠单抗对增生型糖尿病视网膜病变（ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａｂｅｔｉｃｒｅｔｉｎｏｐａｔｈｙ，ＰＤＲ）患者行经平坦部玻璃体切割术（ｐａｒｓｐｌａｎａｖｉｔｒｅｃｔｏｍｙ，ＰＰＶ）效果的影响。方法　回顾性分析１５７例行ＰＰＶ的ＰＤＲ患者，分为ＰＰＶ术前７ｄ行玻璃体内雷珠单抗注射组（Ａ组）及未注射组（Ｂ组）。观察并比较两组ＰＰＶ术中医源性裂孔的发生、填充物应用和术后玻璃体再出血、高眼压及最佳矫正视力情况。结果　Ａ组患者术中医源性裂孔发生占５．６１％，术中填充物应用者占３８．２１％，术后玻璃体再出血者占１５．７３％，术后高眼压者占４３．８２％，治疗稳定后最佳矫正视力＞０．３者占５３．９３％；Ｂ组患者术中医源性裂孔发生占１４．８６％，术中填充物应用者占５５．４１％，术后玻璃体再出血者占３３．７８％，术后高眼压者占５９．４５％，治疗稳定后最佳矫正视力＞０．３者占２１．６２％，两组各项指标比较差异均有统计学意义（Ｐ＝０．０４、０．０２、０．００、０．０４、０．００）。结论　ＰＤＲ患者ＰＰＶ术前行玻璃体内雷珠单抗注射能减少术中医源性裂孔的发生及玻璃体腔填充物的应用，降低术后玻璃体腔再出血及高眼压发生的几率，并可使患者获得较好的术后视力。
Abstract:
Objective To investigate the effectiveness of intravitreal injection of ranibizumab on pars plana vitrectomy ( PPV) for proliferative diabetic retinopathy ( PDR) . Methods A total of 157 patients underwent PPV were analyzed retrospectively,and divided into group A and group B, group A received intravitreal injection of ranibizumab at 7 days before PPV, and group B with no injection. The occurrence of iatrogenic retinal hole , intraocular tamponade , postoperative vitreous re-hemorrhage , post-operative high intraocular pressure and best corrected visual acuity were observed among the two groups. Results In group A,the occurrence of iatrogenic retinal hole and rate of intraocular tamponade application,postoperative vitreous re-hemorrhage and postoperative high intraocular pressure were 5. 61% ,38. 21% , 15. 73% and 43. 82% , respectively. There were 53. 93% patients with a best corrected visual acuity > 0. 3. In group B , the occurrence of iatrogenic retinal hole and rate of intraocular tamponade application ,postoperative vitreous re-hemorrhage and postoperative high intraocular pressure were 14. 86% ,55. 41% ,33. 78% and 59. 45% , respectively. There were 21. 62% patients with a best corrected visual acuity > 0. 3. The difference between the two groups was sigruficant in each date ( P = 0. 04 .0. 02 .0. 00 .0. 04 . 0. 00 ) . Conclrision Intravitreal injection of ranibizumab before PPV for PDR can reduce the occurrence of iatrogenic retinal hole and application of intravitreal tamponade , decrease the incidence of postoperative vitreous hemorrhage and high intraocular pressure , and can lead to a better visual acuity.

相似文献/References:

[1]衡欣 陈悦.增生型糖尿病视网膜病变患者血清中转化生长因子-β1和结缔组织生长因子水平的变化及意义[J].眼科新进展,2013,33(4):000.
[2]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[3]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[4]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[5]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
[6]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
[7]刘斌,杨玉霞,刘杏,等. 雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].眼科新进展,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al. Intravitreal lucentis injection combined with Ahmed valve implantation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
[8]刘志南,邓国华,江一. 光凝前雷珠单抗玻璃体内注射对CNV患者黄斑区视网膜及视功能的影响[J].眼科新进展,2015,35(4):365.[doi:10.13389/j.cnki.rao.2015.0098]
　LIU Zhi-Nan,DENG Guo-Hua,JIANG Yi. Effects of ranibizumab intravitreal injection before photocoagulation on macular retina and visual function in patients with CNV[J].Recent Advances in Ophthalmology,2015,35(3):365.[doi:10.13389/j.cnki.rao.2015.0098]
[9]万文萃,刘宇莹,尹向可,等. 玻璃体内注射抗血管内皮生长因子药物治疗急进性后部型早产儿视网膜病变[J].眼科新进展,2015,35(6):554.[doi:10.13389/j.cnki.rao.2015.0150]
　WAN Wen-Cui,LIU Yu-Ying,YIN Xiang-Ke,et al. Intravitreal injection of ranibizumab for aggressive posterior retinopathy of prematurity[J].Recent Advances in Ophthalmology,2015,35(3):554.[doi:10.13389/j.cnki.rao.2015.0150]
[10]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):566.[doi:10.13389/j.cnki.rao.2015.0153]
[11]赵新荣,杨炜,邱明磊,等.玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变[J].眼科新进展,2015,35(11):1064.[doi:10.13389/j.cnki.rao.2015.0291]
　ZHAO Xin-Rong,YANG Wei,QIU Ming-Lei,et al.Ranibizumab injection and vitrectomy for severe proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(3):1064.[doi:10.13389/j.cnki.rao.2015.0291]
[12]刘爱琴,宋子宣,吴娟,等.雷珠单抗辅助玻璃体视网膜手术治疗增生型糖尿病视网膜病变[J].眼科新进展,2019,39(6):574.[doi:10.13389/j.cnki.rao.2019.0133]
　LIU Ai-Qin,SONG Zi-Xuan,WU Juan,et al.Ranibizumab assisted vitreoretinal surgery for the treatment of proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2019,39(3):574.[doi:10.13389/j.cnki.rao.2019.0133]

更新日期/Last Update: 2016-03-08